Semax vs Selank: What Is the Difference? (Research Overview)

Semax and Selank are both synthetic peptides developed in Russia and widely studied in central nervous system (CNS) and neuropeptide research, but they derive from different parent molecules. In published preclinical literature, Semax is a fragment-derived analog of the adrenocorticotropic hormone sequence ACTH(4–10), while Selank is a synthetic analog of the immunomodulatory peptide tuftsin. Because of these distinct origins, the two are typically associated with different research focuses — Semax with neurotrophic and neuroprotective pathways, and Selank with anxiolytic and immunomodulatory pathways in animal and in-vitro models.

Research-use-only (RUO) note: both Semax and Selank are offered strictly for laboratory and research purposes. The information below summarizes published preclinical (in-vitro and animal) findings and is not intended to describe effects in humans.

Quick comparison

Attribute	Semax	Selank
Origin	Developed in Russia	Developed in Russia
Parent molecule	Fragment-derived analog of ACTH(4–10)	Synthetic analog of tuftsin
Peptide family	Melanocortin / ACTH-fragment class	Tuftsin / immunomodulatory class
Common research focus	Neurotrophic (BDNF) and neuroprotective studies	Anxiolytic and immunomodulatory studies

What is Semax?

Semax is a heptapeptide described in the research literature as a synthetic analog derived from the ACTH(4–10) fragment of adrenocorticotropic hormone. In preclinical models it has been studied for its interaction with neurotrophic signaling, including brain-derived neurotrophic factor (BDNF) pathways in rodent brain tissue. For a deeper background, see our full Semax article.

What is Selank?

Selank is a synthetic peptide based on the structure of tuftsin, a naturally occurring immunomodulatory peptide. In animal and in-vitro studies, Selank is most often examined in the context of anxiolytic-type research and immune/neurotransmitter modulation. For more detail, see our full Selank article.

Key differences studied in the lab

• Semax — ACTH(4–10) / BDNF-related research: preclinical studies have investigated Semax in relation to BDNF protein levels and neurotrophic signaling in rodent brain regions, framing it within neuroprotective research lines.
• Selank — tuftsin analog / anxiolytic and immunomodulatory research: as a tuftsin analog, Selank has been studied in animal models for anxiolytic-type endpoints and for effects on neurotransmitter systems such as serotonin metabolism, as well as immunomodulatory activity.
• Different parent molecules, different pathways: the ACTH-fragment origin of Semax and the tuftsin origin of Selank are the structural reason the two peptides are associated with different mechanistic research questions, even though both are studied in CNS contexts.

Are they studied together?

Yes — Semax and Selank are frequently grouped together in the literature as part of the broader class of Russian-developed regulatory peptides sometimes informally referred to as the “Russian nootropic peptide” research class. Both emerged from the same research tradition of short, sequence-derived regulatory peptides, which is why they are often discussed side by side, despite their different parent molecules and research focuses.

Research status and safety

Both Semax and Selank are supplied here strictly as research-use-only (RUO) materials. As a matter of factual record, both peptides have been registered/approved for certain medical uses within Russia; however, neither is approved by the U.S. Food and Drug Administration (FDA), and neither is approved for human or clinical use in the United States. All summaries above reflect preclinical (in-vitro and animal) research only and should not be interpreted as describing outcomes in people.

Handling

Research peptides such as Semax and Selank are typically supplied as lyophilized powder and require proper preparation before laboratory use. See our reconstitution guide, and browse the full catalog for available research peptides.

FAQ

Are Semax and Selank the same peptide? No. Semax is a fragment-derived analog of ACTH(4–10); Selank is a synthetic analog of tuftsin. They share a common origin in Russian peptide research but differ in structure and the research pathways associated with them.

Which one has more published research? Both have a body of peer-reviewed preclinical literature. Semax is more commonly studied in neurotrophic/BDNF and neuroprotection contexts, whereas Selank is more commonly studied in anxiolytic and immunomodulatory contexts. The right choice depends entirely on the specific research question.

Are these products approved for human use? No. Both are sold strictly for research use only. They are not FDA-approved and are not intended for human consumption, diagnosis, treatment, or prevention of any condition.

References

1. Dolotov OV, et al. Semax, an analogue of ACTH(4-10), increases BDNF protein in rat basal forebrain. J Neurochem. 2006.
2. Kolik LG, et al. Selank, peptide analogue of tuftsin, and BDNF content in rat hippocampus and prefrontal cortex. Bull Exp Biol Med. 2019.
3. Semenova TP, et al. Comparison of the effects of selank and tuftsin on serotonin metabolism in rat brain. Eksp Klin Farmakol. 2009.

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.